Brief: AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA
19/05/2022 14:44
May 19 (Reuters) - AcelRx Pharmaceuticals Inc ACRX.O :
* ACELRX PHARMACEUTICALS PROVIDES UPDATE ON REDUCED FDA REMS
REQUIREMENTS RELATED TO DSUVIA®
Source text for Eikon: ID:nPnbvMqYxa
Further company coverage: ACRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Talphera
See all newsTalphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview
Talphera Q1 net loss narrows as costs rise on higher development spending
Talphera Q4 net loss widens as operating expenses rise
Brief: Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial